行情

MRUS

MRUS

Merus
NASDAQ

实时行情|Nasdaq Last Sale

23.45
+0.71
+3.12%
交易中 10:55 03/08 EST
开盘
23.00
昨收
22.74
最高
23.47
最低
22.23
成交量
1.62万
成交额
--
52周最高
31.27
52周最低
10.18
市值
9.12亿
市盈率(TTM)
-7.9895
分时
5日
1月
3月
1年
5年
Merus参加第33届Roth年会的炉边聊天
UTRECHT, The Netherlands and CAMBRIDGE, Mar 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE...
GlobeNewswire · 2小时前
Merus NV(纳斯达克股票代码:MRUS)获得1.38亿美元承销公开发售
Feb 03, 2021 (Investor Brand Network via COMTEX) -- Merus (NASDAQ: MRUS), focused on the development of innovative, full-length multispecific antibodies, has...
Investor Brand Network · 02/03 18:13
The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More
Biopharma stocks advanced yet again in the week ended Jan. 22, with the change of guard at the White House generating broader market strength.
Benzinga · 01/23 14:14
每日生物技术脉搏:Fluidigm基于唾液的COVID测试在欧洲获得批准,中国支持Amarin的Vascepa
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21)
Benzinga · 01/22 12:22
每日生物技术动向:Addex跳出许可药品的积极数据,COVID-19疫苗开发商Inovio宣布提供1.5亿美元的后续产品,波士顿科学公司开始购物
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 01/21 13:05
礼来公司签署价值高达16亿美元的癌症药物交易
Shares of Eli Lilly & Co. undefined gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with...
MarketWatch · 01/20 12:35
Lilly signs cancer drug deal worth up to $1.6 billion
Shares of Eli Lilly & Co. undefined gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with...
MarketWatch · 01/20 12:35
礼来公司签署价值高达16亿美元的癌症药物交易
Shares of Eli Lilly & Co. undefined gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with...
MarketWatch · 01/20 12:35
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解MRUS最新的财务预测,通过MRUS每股收益,每股净资产,每股现金流等数据分析Merus近期的经营情况,然后做出明智的投资选择。
分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测MRUS价格均价为24.14,最高价位32.00,最低价为15.00。
EPS
机构持股
总机构数: 62
机构持股: 2,466.15万
持股比例: 63.42%
总股本: 3,888.55万
类型机构数股数
增持
14
180.93万
建仓
15
217.63万
减持
10
13.61万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.19%
制药与医学研究
+1.05%
高管信息
Non-Executive Chairman/Independent Director
Anand Mehra
President/Chief Executive Officer/Chief Financial Officer/Executive Director
Sven Lundberg
Non-Executive Vice Chairman/Non-Executive Director
Gregory Perry
Chief Technology Officer
John de Kruif
General Counsel
Peter Silverman
Other
Alexander Bakker
Other
Lex Bakker
Other
Andrew Joe
Other
Hui Liu
Non-Executive Independent Director
Mark Iwicki
Other
L. Andres Sirulnik
Non-Executive Independent Director
Leonard Kanavy
Non-Executive Independent Director
Paolo Pucci
Non-Executive Independent Director
Victor Sandor
暂无数据
MRUS 简况
Merus NV是一家荷兰生物技术公司。该公司为癌症患者开发差异疗法。该公司Merus渠道中的产品项目是基于Biclonics平台。该公司的产品包括用于结合由T细胞表达的两种免疫调节靶标组合的MCLA-134,以及用于在检测点抑制中结合免疫调节靶标与肿瘤相关靶标的MCLA-145。

微牛提供Merus NV(NASDAQ-MRUS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的MRUS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MRUS股票基本功能。